AYAs with cancer: the right to be forgotten by e-ESO Podcasts
Expert: Giuseppe Luigi Banna, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
Related Articles
The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma- A review of the literature
Paraneoplastic neurological syndromes (PNS) are rare neurological disorders arising from malignancy-triggered autoimmunity, yet their association with…
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) – Beyond the Abstract
Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC), Meet-URO score, ZEBRA Study (Meet-URO 9), Cabozantinib, vascular endothelial growth factor (VEGF) inhibitors, metastatic renal cell…
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study
Scientific Reports – Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study
Listen to what Monty Pal told at IUCS23 on first-line therapy for mRCC
Watch this videoclip from the Monty Pal presentation at #IUCS23 titled “How to choose first-line therapy for mRCC”
Listen to what Monty Pal told at IUCS23 on first-line therapy for mRCC
Watch this videoclip from the Monty Pal presentation at #IUCS23 titled “How to choose first-line therapy for mRCC”
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer | NEJM
Original Article from The New England Journal of Medicine — Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Lung Cancer
This randomized clinical trial compares progression-free survival using treatment with atezolizumab plus carboplatin with pemetrexed vs atezolizumab, carboplatin with pemetrexed, and bevacizumab in patients with…
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Molecular Testing in Non–Small-Cell Lung Cancer: A Call to Action
It has been nearly 15 years since the IPASS trial first demonstrated the importance of molecular testing to identify the population of patients with non–small-cell…
Listen to what Gopi Gnanasegaran told at #IUCS23 about diagnostic #PSMA PET
Watch this videoclip from the Gopi Gnanasegaran presentation at #IUCS23 titled “Theragnostics in mPCa: Diagnosis and Treatment”